ZEP2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Eurofins-Cerep SA News
ZEP2 FAQ
What was Eurofins-Cerep SA’s price range in the past 12 months?
Currently, no data Available
What is Eurofins-Cerep SA’s market cap?
Eurofins-Cerep SA’s market cap is €91.81M.
When is Eurofins-Cerep SA’s upcoming earnings report date?
Eurofins-Cerep SA’s upcoming earnings report date is Sep 17, 2026 which is in 16 days.
How were Eurofins-Cerep SA’s earnings last quarter?
Eurofins-Cerep SA released its earnings results on Sep 18, 2025. The company reported €360.825 earnings per share for the quarter.
Is Eurofins-Cerep SA overvalued?
According to Wall Street analysts Eurofins-Cerep SA’s price is currently Undervalued.
Does Eurofins-Cerep SA pay dividends?
Eurofins-Cerep SA does not currently pay dividends.
What is Eurofins-Cerep SA’s EPS estimate?
Eurofins-Cerep SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eurofins-Cerep SA have?
Eurofins-Cerep SA has 5,045 shares outstanding.
What happened to Eurofins-Cerep SA’s price movement after its last earnings report?
Eurofins-Cerep SA reported an EPS of €360.825 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Eurofins-Cerep SA?
Currently, no hedge funds are holding shares in DE:ZEP2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurofins-Cerep SA
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.
bioMerieux
―
Eurofins Scientific
―
Novacyt
―
Eurobio-Scientific SA
―
ABL Diagnostics SA
―